Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis

Author's Avatar
Sep 15, 2018
Article's Main Image

PR Newswire